FindTrial
Sign In

Performance evaluation of new rapid respiratory viral infection diagnostic test

Prospective Pilot-Scale Validation Study For The Evaluation Of Performance Of Achiras Multiplexed IVD Product for the Detection of Covid-19, Flu A, Flu B, and RSV Respiratory Viruses, V1, 02/06/2025 - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098937
Enrollment
80
Registered
2025-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J06- Acute upper respiratory infections

Interventions

Intervention1: Achira RPT: Achiras respiratory viral panel test is designed for the detection of Covid-19, Flu A, Flu B, and RSV. The test will be done on all patients nasal samples. Control Intervent

Sponsors

Achira Labs Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients prescribed for respiratory virus testing at CLoudnine

Exclusion criteria

Exclusion criteria: Patient with non-respiratory illness as assessed by clinician

Design outcomes

Primary

MeasureTime frame
Detection of any of the four respiratory viruses in the collected nasal samples.Timepoint: The recommendation for the test will be guided by the investigator. The test will be conducted when the patient visits the doctor. If the doctor prescribes the patient for the study, the test will be run on the patients nasal sample immediately.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactRohini K

Cloudnine Hospital

drkishore@cloudninecare.com9972899728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026